SCM
RXDX

Suvretta Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Suvretta Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-480,480
Closed -$11.4M – 121
2021
Q3 		$11.4M Sell
480,480
-145,145
-23% -$3.43M 0.19% 65
2021
Q2 		$15.4M Buy
625,625
+47,091
+8% +$1.05M 0.23% 66
2021
Q1 		$10.6M Buy
+578,534
New +$11.9M 0.16% 74

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Suvretta Capital Management's RXDX Position: Q4 2021 in Review

Suvretta Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2021, closing a stake of 480,480 shares — an estimated $11.4M sold.

Suvretta Capital Management first reported a position in RXDX in Q1 2021 and held it in 3 quarters. The position peaked at $15.4M in Q2 2021. 74 funds tracked by Wall St. Rank hold RXDX as of Q4 2021.

  • Suvretta Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 480,480 Prometheus Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $11.4M.
  • Suvretta Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Suvretta Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $15.4M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2021.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.